LPCN
- Lipocine Inc.
()
Overview
Company Summary
Lipocine Inc. (LPCN) is a pharmaceutical company primarily focused on the development of oral testosterone replacement therapies (TRTs) for men. TRTs are used to treat various conditions caused by low testosterone levels, such as hypogonadism, which is the inadequate production of testosterone due to an underlying medical condition.
Unlike traditional testosterone replacement methods like injections or gels, Lipocine aims to provide a convenient and non-invasive oral alternative. The company's proprietary technology platform, known as Lip'ral, enables the oral delivery of testosterone by enhancing the solubility and absorption characteristics of the hormone.
Lipocine's lead product candidate is TLANDO�, an oral TRT designed to restore normal testosterone levels in hypogonadal men. TLANDO� has undergone clinical trials and Lipocine has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its approval. The company is also exploring other potential applications of its Lip'ral technology for the development of additional oral medications.
In addition to advancing its product pipeline, Lipocine also pursues strategic partnerships with pharmaceutical companies and healthcare organizations to support the commercialization and distribution of its products on a global scale. By addressing the unmet needs in testosterone replacement therapy, Lipocine aims to improve the quality of life for men suffering from low testosterone levels while offering a more accessible treatment option.